This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Evidence-Based Medicine  • Randomized Controlled Trial  • Prognosis/ Outcomes  • Bipolar Disorder  • Drug Therapy  • Alert me on articles by topic

A Systematic Review and Meta-analysis of Randomized Controlled Trials

Harald Scherk, MD; Frank Gerald Pajonk, MD, PhD; Stefan Leucht, MD, PhD

Arch Gen Psychiatry. 2007;64(4):442-455.

Context  Recommendations of treatment guidelines concerning the use of second-generation antipsychotic (SGA) agents for acute mania vary substantially across committees or working groups. Meta-analyses addressing the use of SGAs in the treatment of acute mania are lacking.

Objective  To conduct a meta-analysis of the efficacy and safety of SGAs in the treatment of acute mania.

Data Sources  Randomized controlled trials comparing SGAs with placebo, first-generation antipsychotic drugs, or mood stabilizers (MSs) in the treatment of acute mania were searched for in the PsiTri and MEDLINE databases (last search: May 2006).

Study Selection  The abstracts, titles, and index terms of studies were searched using the following key words: aripiprazole, amisulpride, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, and zotepine in conjunction with mania, manic, and bipolar.

Data Extraction  Data on efficacy, global dropout, dropout due to adverse events, dropout due to inefficacy, weight gain, rate of somnolence, and extrapyramidal symptoms were extracted and combined in a meta-analysis.

Data Synthesis  A total of 24 studies with 6187 patients were included. The SGAs were significantly more efficacious than placebo. The analysis demonstrated that adding antipsychotic agents to MS treatment was significantly more effective than treatment with MSs alone. The SGAs displayed efficacy comparable with that of MSs. Some SGAs seemed to induce more extrapyramidal symptoms than placebo. The SGAs were also associated with higher rates of somnolence than placebo.

Conclusion  Currently available data suggest that combining SGAs and MSs is the most efficacious treatment of acute mania.

Author Affiliations: Department of Psychiatry and Psychotherapy, Georg-August University Goettingen, Goettingen (Dr Scherk), Center for Psychiatric and Psychotherapeutic Care and Rehabilitation, Dr K. Fontheim's Hospital for Mental Health, Liebenburg (Dr Pajonk), and Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universität München, Munich (Dr Leucht), Germany.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical Trials in Bipolar Mania: Implications in Study Design and Drug Development
Tohen
Arch Gen Psychiatry 2008;65:252-253.
FULL TEXT  

Protein Kinase C Inhibition in the Treatment of Mania: A Double-blind, Placebo-Controlled Trial of Tamoxifen
Yildiz et al.
Arch Gen Psychiatry 2008;65:255-263.
ABSTRACT | FULL TEXT  

Methodological Issues in Current Antipsychotic Drug Trials
Leucht et al.
Schizophr Bull 2008;34:275-285.
ABSTRACT | FULL TEXT  

Olanzapine and Pediatric Bipolar Disorder: Evidence for Efficacy and Safety Concerns
McClellan
Am. J. Psychiatry 2007;164:1462-1464.
FULL TEXT  

Review: Antipsychotic plus mood stabiliser co-therapy is more effective than mood stabiliser mono-therapy at reducing acute bipolar mania
Cipriani et al.
Evid. Based Ment. Health 2007;10:83-83.
FULL TEXT  

The Neuropharmacology of Psychosis
Tamminga and Davis
Schizophr Bull 2007;33:937-946.
ABSTRACT | FULL TEXT  

How Good Are the Atypical Antipsychotics for Mania?
JWatch Psychiatry 2007;2007:2-2.
FULL TEXT